Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy.
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | $198,736.23 | 33,700 | 2023-12-12 | Filing | |
| $32.48 | 10,000 | $324,846.00 | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | $1,999,995.00 | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | $337,230.00 | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | $12,460.00 | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64.97 | 312 | $20,270.64 | 103,901 | 2025-10-07 | Filing | |
| $63.80 | 1,306 | $83,322.80 | 104,213 | 2025-10-07 | Filing | |
| $62.89 | 1,757 | $110,497.73 | 105,519 | 2025-10-07 | Filing | |
| $66.89 | 1,884 | $126,020.76 | 10,332 | 2025-10-03 | Filing | |
| $66.10 | 4,037 | $266,845.70 | 12,216 | 2025-10-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 503,966 | $30,928,393 | 0.08% | |
| 2. | 284,891 | $17,483,761 | 0.02% | |
| 3. | 132,101 | $8,107,038 | 0.01% | |
| 4. | 107,648 | $6,606,358 | 0.01% | |
| 5. | 4,773,000 | $6,121,373 | 0.42% |
News See All
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the launch of SUFIANCE (sepiapterin) for phenylketonuria (PKU).
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded.
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire David E. Shaw's 10 Small-Cap Stock Picks with Huge Upside Potential
David E. Shaw is one billionaire investor whose record speaks for itself on Wall Street. Having founded D.E. Shaw & Co., L.P.
Hedge Fund Resource Center Billionaire Hedge Funds
